Brian Scanlan

Brian Scanlan is a life sciences executive, investor, board member, and strategic advisor with more than 35 years of experience across the pharmaceutical and CRO/CDMO industries. He is currently Managing Partner of Freedom Bioscience Partners, where he advises CRO/CDMO’s, and life science technology companies in various areas including strategic growth, funding, commercial development, and strategic partnerships. He also serves on boards, invests in emerging companies, and works closely with founder-led businesses, leveraging his extensive industry network to create high-impact commercial and strategic opportunities. He remains active as a thought leader in the biotech and CDMO markets, contributing to industry platforms including CPhI, DCAT, Pharma Manufacturing, and Interphex.

Prior to this, he spent nearly 25 years in CDMO leadership, progressing from the laboratory to the CEO chair. His last operating role was CEO of Cambridge Major Laboratories where he lead its merger with AAI Pharma to create Alcami in 2013. He subsequently transitioned into private equity, advising and serving as an industry expert to investment firms before building/ leading the Life Science investment practice at Edgewater Capital.